Articles

Drug-coated stents appear to be superior to bare metal stents in both efficacy and safety in patients with diabetes, new research shows.

A large waist circumference is related to a higher risk of death even for individuals who have the same BMI [body mass index, a ratio of weight to height].

GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone) has failed to show it can significantly reduce atherosclerosis in patients with type 2 diabetes.

More than half of Americans with chronic illnesses did not fill prescriptions, skipped doses of their medications, or didn’t see a doctor for a medical problem because they could not afford to, a new study showed.

While we are waiting for a once a day and once a week injectable GLP-1(exentide-4), Oramed Pharmaceuticals presented the results of a once a day oral administration of exenatide-4. 

A new observational study finds an association between higher levels of nonfasting triglycerides and increasing risk for ischemic stroke.

President-elect Barack Obama’s plans to overhaul the U.S. health care system would cost the federal government $75 billion but would provide health insurance for 95 percent of Americans.

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982.

The Endocrine Society has released a new clinical practice guideline for the primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk.

Aspirin therapy is commonly used for primary prevention of cardiovascular events in persons with type 2 diabetes, but a Japanese study of 2,539 subjects found no statistically significant reduction in the primary end point of total atherosclerotic events, except in patients aged at least 65 years.